Baygam Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to high rabies mortality rates, reliance on immunoglobulin therapy, limited early vaccination coverage, growth of emergency care services, public health awareness campaigns.

The growth in the forecast period can be attributed to increasing animal bite incidents, expansion of vaccination programs, rising healthcare access in developing regions, improved cold chain distribution, government supported rabies control initiatives. Major trends in the forecast period include rising demand for post exposure prophylaxis, expansion of rabies prevention programs, increased use of passive immunization therapies, growing hospital and clinic administration of hrig, strengthening of emergency infectious disease care.

The increasing prevalence of immunodeficiency diseases is expected to drive the growth of the baygam market in the coming years. Immunodeficiency diseases are disorders in which the immune system is absent or weakened, reducing its ability to combat infections and other illnesses. The rise in these conditions is driven by better diagnosis and awareness, as well as an aging population with naturally weakened immune systems, making individuals more susceptible to infections and immune-related disorders. Baygam supports patients with immunodeficiency diseases by providing intravenous immunoglobulin (IVIG) therapy, replenishing essential antibodies and enhancing the immune system’s ability to fight infections. This therapy helps reduce the frequency and severity of bacterial and viral infections in individuals with compromised immunity. For example, in October 2024, the UK Health Security Agency reported 6,008 HIV diagnoses in England in 2023 (including individuals previously diagnosed abroad), representing a 51% increase from 3,975 cases in 2022. Therefore, the growing prevalence of immunodeficiency diseases is contributing to the expansion of the baygam market.

The rising healthcare expenditure is expected to support the growth of the baygam market. Healthcare expenditure refers to the total financial resources allocated to healthcare services, including treatments, hospital care, medications, and public health initiatives, by governments, businesses, and individuals. Increasing healthcare spending is driven by the growing prevalence of chronic diseases, which require long-term and often costly care. Higher healthcare expenditure facilitates the utilization of baygam by improving access to essential immunoglobulin therapies and strengthening healthcare infrastructure. This ensures timely treatment for immune deficiencies and related conditions, enhancing patient outcomes and preventive care. For example, in May 2024, the Office for National Statistics, a UK-based government department, reported that total healthcare expenditure in 2023 increased by 5.6% in nominal terms, compared with 0.9% growth in 2022. Therefore, rising healthcare expenditure is driving the growth of the baygam market.

In March 2023, Selagine, Inc., a U.S.-based company focused on novel therapeutics, partnered with Grifols S.A. This collaboration aims to develop innovative immunoglobulin eye drops for treating dry eye disease (DED), combining Grifols' expertise in plasma-derived therapies with Selagine's ocular treatment research to address a major unmet medical need affecting over 100 million people worldwide. Grifols S.A., based in Spain, specializes in developing and producing plasma-derived medicines, including various immune globulin therapies.

Major companies operating in the baygam market are Grifols S.A.

North America was the largest region in the baygam market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the baygam market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the baygam market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the baygam market by increasing costs related to plasma sourcing, immunoglobulin purification, and sterile packaging materials. These cost pressures have affected hospital and clinic procurement, particularly in import dependent regions. Asia pacific and africa experience higher sensitivity due to reliance on international plasma products. However, tariffs have encouraged local plasma collection programs, regional manufacturing expansion, and improved long term availability of rabies prophylaxis therapies.

The baygam market research report is one of a series of new reports that provides baygam market statistics, including baygam industry global market size, regional shares, competitors with a baygam market share, detailed baygam market segments, market trends and opportunities, and any further data you may need to thrive in the baygam industry. This baygam market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Baygam is a human rabies immunoglobulin (HRIG) used for post-exposure prophylaxis (PEP) in individuals who may have been exposed to the rabies virus. It is usually administered alongside the rabies vaccine to provide immediate passive immunity while the body develops its own active immune response through vaccination.

The primary indications for Baygam include primary immunodeficiency, secondary immunodeficiency, chronic inflammatory demyelinating polyneuropathy, and Guillain-Barré syndrome. Primary immunodeficiency refers to a group of disorders in which the immune system is inherently impaired from birth, resulting in increased susceptibility to infections. Baygam is distributed through hospitals, clinics, and home care services and is used by a range of end users, including adults, geriatric, and pediatric patients.

The baygam market consists of sales of products including imogam, hyperrab, kedrab, rabishield, and bayrab. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.